tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Orthocell Achieves Record Revenue and Expands Global Reach

Story Highlights
  • Orthocell Limited achieved a record revenue of $3.0 million, driven by Remplir’s growth.
  • Orthocell is expanding Remplir’s market presence in the US and Canada, targeting further growth.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Orthocell Achieves Record Revenue and Expands Global Reach

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.

Orthocell Limited reported a record quarterly revenue of $3.0 million, marking the sixth consecutive quarter of growth, driven by the increasing market penetration of its nerve repair product, Remplir, in Australia and Singapore. The company is strategically expanding its commercial operations in the US and Canada, with early successes in the US market and plans for further growth in North America. The use of Remplir in nerve-sparing prostate cancer surgeries presents a significant opportunity to expand its market reach, while recent leadership appointments are expected to strengthen its operational capabilities.

The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.

More about Orthocell Ltd

Orthocell Limited is a regenerative medicine company focused on developing and commercializing innovative medical devices. The company primarily operates in the nerve repair market, with its flagship product, Remplir, gaining significant traction in Australia, Singapore, and expanding into the US and Canadian markets.

Average Trading Volume: 573,334

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$359.4M

Learn more about OCC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1